Key Takeaways
- Jammu facility is the FY26 story: Commercial production began January 2025, and management targets ₹400–500 crores of incremental revenue in FY26, with a path to ₹1,000 crores in 2–3 years.
- Sharon revenue deferred, not lost: Q3 revenue fell 6.5% YoY as international customers pushed ~₹250 crores of orders into Q4; the miss is expected to be fully recovered.
- Margins held up despite mix shift: PAT margin improved to 10.8% from 8.3%, helped by better EBITDA and lower interest costs, even as the higher-margin Sharon business dipped.
- Management confirmed 25%+ growth next year: When asked directly, the answer was "Yes, of course," though the company declined to give a formal consolidated revenue guidance.
- What to watch next quarter: Whether the deferred Sharon orders actually land in Q4, the first revenue contribution from Jammu (guided at ₹20–40 crores), and any further color on FY26 margin trajectory as the plant ramps.
Jammu Facility: The Growth Engine
- Operational milestone: Commercial production began 14 January 2025 at the Kathua, Jammu facility, adding three new production blocks covering blow fill seal (LVP and respules), dry powder injectables, penicillin, and an extension of the existing cephalosporin block from Baddi.
- Revenue ambition: Management expects ₹400–500 crores of incremental revenue in FY26, with ~₹50–60 crores of transferred business from existing sites, taking total Jammu contribution to ₹450–550 crores. The plant is targeted to reach ₹1,000 crores within 2–3 years.
- Capacity utilization path: Initial year sees a large leap to 30–35% utilization; year two to three reaches 50–55%; after three to four years, growth moderates to ~10% annually. Most of the growth is covered up to FY28 (70–80% utilization), with 10–12% growth in FY29 and FY30.
- Margin profile: Once stabilized at the ₹400–500 crores run-rate, Jammu margins should align with the base business at 15–16% EBITDA. Over the long term, GST-linked incentives (300% of eligible plant and machinery investment for up to 10 years) and capital interest subvention (~600 bps reduction) are expected to push stabilized margins slightly above baseline.
- Q4 FY25 contribution: A small revenue contribution of ₹20–40 crores is expected in Q4 FY25, with production having started mid-January.
- Workforce readiness: Critical positions (plant head, QA, QC, regulatory affairs) were filled one to two years ago during construction. Broader recruitment used word of mouth, walk-ins, references, and portals across the country.
- Product pipeline: Over 30 products have already been developed in R&D for the Jammu facility, with process validation and data generation underway.
Lohariwala: "We have already developed almost 30-plus products in our R&D and that will be rolled to the production floor. We have started doing the process validation and generation of the data."
Sharon: The Deferred Quarter
- Revenue decline explained: Sharon revenue was 6.5% below last year because certain international customers with December year-end closings deferred delivery to Q4. The deferred amount was ~₹250 crores, with a smaller ₹4–5 crores of orders also pushed out.
- Recovery expected in Q4: Management stated the Q3 hit is expected to be covered in Q4, implying a strong March quarter for the subsidiary.
- Growth and margin outlook intact: Sharon is expected to grow in the early teens in coming years, with margins remaining stable at current levels.
- Gross margin effect: The lower Sharon revenue contribution in Q3 paradoxically helped consolidated gross margin percentage, since Sharon carries a higher gross margin than the rest of the business. Product mix changes and a CDMO price reduction (pass-through model) also played a role.
CDMO & Domestic Generic: The Steady Base
- CDMO growth drivers beyond IPM: CDMO growth is fueled not just by domestic pharma market expansion but by product shifts: site-to-site transfers and in-house to outsourced manufacturing moves. Volumes increased year-on-year, with standalone revenue up ~7–8% after adjusting for pricing.
- API pricing stable sequentially: QoQ API prices are stable from the company's perspective, though YoY there is a slight decline. Going forward, management expects a stable environment with a mix of small price decreases and increases.
- Domestic generic seasonality: Q2 and Q3 are typically the top quarters due to seasonal demand (September/October peak). Over nine months, domestic generic grew 18%.
- Manufacturing capability as moat: The company's manufacturing capability drives all business segments (CDMO, domestic generic, international generic), and the Jammu facility is designed to increase wallet share with top Indian domestic players under an 80:20 rule.
Lohariwala: "So there the growth comes not only from the IPM growth but from the product shift also. The product shift may be from site to site or from in-house to site."
Margins: Gradual Improvement Path
- PAT margin improved: PAT margins rose to 10.8% from 8.3%, driven by better EBITDA margins and a reduction in interest cost.
- Long-term EBITDA trajectory: Blended margins currently sit at 15.5–16%. As Jammu ramps up and other business contributes, long-term margins are expected to be slightly higher, though management declined to quantify the improvement beyond saying 100–200 bps is possible. A clearer picture will emerge as Jammu matures over the next year.
- Depreciation headwind: Annual depreciation from the Jammu plant is estimated at ₹20–25 crores, which will weigh on reported margins during the ramp-up phase.
- GST incentive tailwind: The Jammu facility is eligible for a GST-linked incentive of 300% of investment in eligible plant and machinery for up to 10 years, plus capital interest subvention reducing interest cost by approximately 600 bps. These benefits accrue to gross margin over time.
International Expansion & Regulatory Positioning
- New regulated market entries: The company recently expanded its footprint into Canada and the UK, which management believes will drive future growth.
- Schedule M stance: Management emphasized that its facilities are well compliant with both domestic and international regulations and that it relies on its own strengths and relationships with large domestic players rather than speculating on government implementation timelines. The Jammu facility was designed with a 40–50 year horizon.
Lohariwala: "Our facility is well compliant and we have our own sense rather than speculating on the government implementation of the Schedule M and all that. We have our own strength."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Jammu facility revenue | ₹400–500 crores incremental revenue (₹450–550 crores total including transfers) | FY26 |
| Jammu Q4 FY25 revenue | ₹20–40 crores | Q4 FY25 |
| Jammu path to scale | Reach ₹1,000 crores | 2–3 years |
| Jammu capacity utilization | 30–35% initial year; 50–55% by year 2–3; ~10% growth thereafter | FY26–FY30 |
| Jammu stabilized margin | In line with base business at 15–16% EBITDA | Once at ₹400–500 crores run-rate |
| Jammu annual depreciation | ₹20–25 crores per annum | Ongoing from commercialization |
| Sharon growth | Early teens growth | Coming years |
| Sharon margin | Stable at current levels | Coming years |
| Overall growth next year | 25%+ (confirmed "Yes, of course") | FY26 |
| Long-term margin improvement | 100–200 bps possible; clearer picture after one year | FY27/FY28 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Consolidated revenue | ₹316.5 cr, +5% YoY |
| CDMO revenue | ₹172.2 cr, 54% of topline |
| Domestic generic revenue | ₹58.6 cr, 19% of topline |
| International generic revenue | ₹41.2 cr, +17% YoY, 13% of topline |
| Sharon revenue | ₹44.5 cr, -6.5% YoY, 14% of topline |
| EBITDA | ₹50.9 cr, margin 16.1%, +60 bps YoY |
| Profit after tax | ₹34.2 cr, +36.3% YoY |
| PAT margin | 10.8%, vs 8.3% in Q3 FY24 |
| 9M FY25 consolidated revenue | ₹928.9 cr, +13.5% YoY |
| 9M FY25 CDMO revenue | ₹505.1 cr |
| 9M FY25 domestic generic revenue | ₹169 cr, +18% YoY |
| 9M FY25 international generic revenue | ₹113 cr |
| 9M FY25 Sharon revenue | ₹141.9 cr |
| CDMO volume growth (9M YoY) | early teens |
| Jammu facility Q4 FY25 revenue estimate | ₹20 cr to ₹40 cr |
| Jammu facility FY26 revenue target | ₹400 cr to ₹500 cr incremental |
| Jammu facility peak utilization | 70% to 75%, revenue potential of ₹1,500 cr to ₹1,600 cr |
| Jammu facility annual depreciation estimate | ₹20 cr to ₹25 cr |
| Jammu facility current headcount | 500 to 600 plus apprentices |
| Jammu facility peak headcount | 1,200 to 1,300 |
| Distribution touch points | 1,50,000 |
| Domestic product portfolio | 600 products |
| Export countries | 25 |
| Manufacturing facilities | 5 facilities, 9 independent production blocks |
| GST-linked incentive on Jammu investment | 300% of eligible plant and machinery investment, available up to 10 years |
| Interest cost reduction on Jammu loans | ~600 bps via capital interest subvention |
| Sharon deferred orders (Q3 to Q4) | ₹4 cr to ₹5 cr |
| Blended consolidated EBITDA margin range | 15.5% to 16% |